MASI: microbiota-active substance interactions database.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
08 01 2021
Historique:
accepted: 07 10 2020
revised: 28 09 2020
received: 15 08 2020
pubmed: 31 10 2020
medline: 27 1 2021
entrez: 30 10 2020
Statut: ppublish

Résumé

Xenobiotic and host active substances interact with gut microbiota to influence human health and therapeutics. Dietary, pharmaceutical, herbal and environmental substances are modified by microbiota with altered bioavailabilities, bioactivities and toxic effects. Xenobiotics also affect microbiota with health implications. Knowledge of these microbiota and active substance interactions is important for understanding microbiota-regulated functions and therapeutics. Established microbiota databases provide useful information about the microbiota-disease associations, diet and drug interventions, and microbiota modulation of drugs. However, there is insufficient information on the active substances modified by microbiota and the abundance of gut bacteria in humans. Only ∼7% drugs are covered by the established databases. To complement these databases, we developed MASI, Microbiota-Active Substance Interactions database, for providing the information about the microbiota alteration of various substances, substance alteration of microbiota, and the abundance of gut bacteria in humans. These include 1,051 pharmaceutical, 103 dietary, 119 herbal, 46 probiotic, 142 environmental substances interacting with 806 microbiota species linked to 56 diseases and 784 microbiota-disease associations. MASI covers 11 215 bacteria-pharmaceutical, 914 bacteria-herbal, 309 bacteria-dietary, 753 bacteria-environmental substance interactions and the abundance profiles of 259 bacteria species in 3465 patients and 5334 healthy individuals. MASI is freely accessible at http://www.aiddlab.com/MASI.

Identifiants

pubmed: 33125077
pii: 5943835
doi: 10.1093/nar/gkaa924
pmc: PMC7779062
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

D776-D782

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Nat Prod Rep. 2019 May 22;36(5):788-809
pubmed: 30534698
Lancet Oncol. 2019 Feb;20(2):e77-e91
pubmed: 30712808
Science. 2019 Jul 12;365(6449):
pubmed: 31296738
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Protein Cell. 2018 May;9(5):432-445
pubmed: 29705929
PLoS One. 2013 Aug 06;8(8):e70803
pubmed: 23940645
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11951-E11960
pubmed: 30510004
Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13839-13845
pubmed: 32471946
Nat Commun. 2020 Mar 18;11(1):1427
pubmed: 32188862
Clin Transl Sci. 2020 Mar;13(2):238-259
pubmed: 31675176
Nat Methods. 2017 Oct 31;14(11):1023-1024
pubmed: 29088129
Science. 2019 Feb 8;363(6427):
pubmed: 30733391
Nature. 2018 Mar 29;555(7698):623-628
pubmed: 29555994
Sci Total Environ. 2020 Jan 20;701:134684
pubmed: 31704402
Future Med Chem. 2020 Jul;12(13):1197-1200
pubmed: 32466672
Gut. 2020 Aug;69(8):1510-1519
pubmed: 32409589
Nucleic Acids Res. 2018 Jan 4;46(D1):D1217-D1222
pubmed: 29106619
Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):461-478
pubmed: 31123355
Eur J Nutr. 2018 Feb;57(1):1-24
pubmed: 28393285
Nat Rev Microbiol. 2011 Apr;9(4):233-43
pubmed: 21358670
Cell. 2016 Nov 3;167(4):1125-1136.e8
pubmed: 27814509
Toxicol Sci. 2020 Aug 1;176(2):253-284
pubmed: 32392306
Nucleic Acids Res. 2012 Jan;40(Database issue):D136-43
pubmed: 22139910
Microbiome. 2014 Jun 17;2:20
pubmed: 24967088
Nucleic Acids Res. 2017 Jan 4;45(D1):D955-D963
pubmed: 27899599
Science. 2017 Jun 23;356(6344):
pubmed: 28642381
Therap Adv Gastroenterol. 2013 Jan;6(1):39-51
pubmed: 23320049
J Infect. 2019 Dec;79(6):471-489
pubmed: 31629863
Med Res Rev. 2017 Sep;37(5):1140-1185
pubmed: 28052344
BMC Microbiol. 2018 Jun 4;18(1):50
pubmed: 29866037
Nucleic Acids Res. 2019 Jul 2;47(W1):W256-W259
pubmed: 30931475
Pharmacol Rev. 2019 Apr;71(2):198-224
pubmed: 30890566
Nucleic Acids Res. 2020 Jan 8;48(D1):D9-D16
pubmed: 31602479
Nucleic Acids Res. 2020 Jan 8;48(D1):D1031-D1041
pubmed: 31691823
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nucleic Acids Res. 2019 Jan 8;47(D1):D930-D940
pubmed: 30398643
J Agric Food Chem. 2017 Sep 6;65(35):7599-7606
pubmed: 28727425
BMC Biol. 2016 Jan 11;14:3
pubmed: 26754945
Nucleic Acids Res. 2019 Jan 8;47(D1):D614-D624
pubmed: 30371894
Gut Microbes. 2016 Nov;7(6):471-485
pubmed: 27624382
Front Microbiol. 2017 Oct 06;8:1935
pubmed: 29056933
Nat Biotechnol. 2019 Feb;37(2):179-185
pubmed: 30718868
NPJ Biofilms Microbiomes. 2016 May 04;2:16003
pubmed: 28721242
Nucleic Acids Res. 2020 Jan 8;48(D1):D554-D560
pubmed: 31584099
Trends Pharmacol Sci. 2019 Jun;40(6):430-445
pubmed: 31079848
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989
J Nat Prod. 2016 Dec 23;79(12):3022-3030
pubmed: 28006907
Nature. 2019 Jun;570(7762):462-467
pubmed: 31158845

Auteurs

Xian Zeng (X)

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, P. R. China.

Xue Yang (X)

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, P. R. China.

Jiajun Fan (J)

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, P. R. China.

Ying Tan (Y)

The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua University Shenzhen Graduate School, Shenzhen Technology and Engineering Laboratory for Personalized Cancer Diagnostics and Therapeutics, Shenzhen Kivita Innovative Drug Discovery Institute, Guangdong, P. R. China.

Lingyi Ju (L)

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, P. R. China.

Wanxiang Shen (W)

Bioinformatics and Drug Design group, Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore.

Yali Wang (Y)

Bioinformatics and Drug Design group, Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore.

Xinghao Wang (X)

The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua University Shenzhen Graduate School, Shenzhen Technology and Engineering Laboratory for Personalized Cancer Diagnostics and Therapeutics, Shenzhen Kivita Innovative Drug Discovery Institute, Guangdong, P. R. China.

Weiping Chen (W)

Key Lab of Agricultural Products Processing and Quality Control of Nanchang City, Jiangxi Agricultural University, Nanchang, 330045, P. R. China.

Dianwen Ju (D)

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, P. R. China.

Yu Zong Chen (YZ)

Bioinformatics and Drug Design group, Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH